Reimbursed Care Access in Saint Barthélemy

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. The French arrêté fixing the list of substances classées comme stupéfiants explicitly lists psilocybin/psilocin as controlled substances. #

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (3,4‑methylenedioxymethamphetamine) is explicitly listed in the French arrêté des stupéfiants. #

Esketamine (SPRAVATO) is marketed and regulated in France with a hospital‑focused access pathway and a tightly circumscribed reimbursement decision. The European Marketing Authorization (EMA) led to SPRAVATO’s market availability, and in France the Haute Autorité de Santé (HAS) reassessed SPRAVATO and issued an opinion limiting the clinical situations in which reimbursement is justified: reimbursement is maintained only in association with an SSRI or SNRI, for adults under 65 with treatment‑resistant major depressive episodes who have failed at least two different antidepressants of two different classes during the current severe episode; HAS concluded the service médical rendu (SMR) is insufficient for other AMM situations. # The French government publication (arrêté) formalized the restrictive reimbursement listing for SPRAVATO (publication modifying the list of specialties eligible for public coverage), confirming the narrow indication for prise en charge par l'assurance maladie. # Operationally, SPRAVATO is subject to specific risk‑minimisation measures, hospital-centred prescription/administration rules, and local hospital authorization/agreements; access in Saint Barthélemy follows French regulatory and hospital pathways because the collectivity applies French laws. #

Ketamine is an authorized medicinal product in France for anesthetic and certain analgesic uses and is regulated by French health authorities; it is therefore legally available in medical settings (hospitals, emergency departments) and reimbursed when used for approved anesthetic/analgesic indications. The HAS has evaluated esketamine and has also issued assessments relating to ketamine/esketamine uses in anesthesia; ketamine as an anesthetic is part of standard practice and covered within hospital funding mechanisms. # For psychiatric (antidepressant) use, ketamine is commonly used off‑label in specialist centres and research settings; such off‑label psychiatric uses are generally not reimbursed by the French national insurance unless specifically covered under an approved, funded hospital program or dedicated national decision. There is no broad outpatient reimbursement for off‑label ketamine for depression in France, and professional guidance and ANSM oversight apply to hospital protocols. #

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. French legal texts and subsequent amendments list DMT (N,N‑diméthyltryptamine) among controlled tryptamines in the stupéfiants lists. # #

Currently classified as a strictly controlled substance in practice under French drug control frameworks for tryptamine derivatives; there is limited, molecule‑specific consistency across amendments, and French public health information pages state that while some newer analogues may not have been named expressly in older texts, the regulatory approach treats many 5‑MeO and other potent tryptamines as controlled or subject to enforcement unless an explicit, up‑to‑date exemption exists. For example, the French drug‑information service noted that as of its review certain 5‑MeO derivatives were not listed while DMT and many tryptamines are listed; nonetheless, routine legal position and enforcement treat 5‑MeO‑type powerful tryptamines as controlled or prosecutable if intended for human consumption absent a specific legal carve‑out. For the definitive legal position in a given moment, the arrêté lists and ANSM/Ministry of Health publications should be consulted. # #

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not approved for medical treatment in France and its importation, possession or administration outside approved research contexts would fall under narcotics prohibitions and public‑health enforcement. Consult the national lists of stupéfiants and ANSM guidance for research exceptions. #

Currently classified as a strictly controlled substance under national drug scheduling laws when it contains controlled alkaloids (notably DMT/harmala alkaloids) and thus has no authorized medical use outside of approved clinical research. French regulatory history shows explicit inclusion of ayahuasca and its common plant ingredients in amendments to the stupéfiants list (making decoctions or preparations containing these controlled alkaloids subject to the law). Religious or traditional‑use exceptions are not broadly recognized outside narrow, case‑by‑case judicial decisions; in practice ayahuasca use is prohibited except in authorized research. # #

Currently classified as a strictly controlled substance under French national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is explicitly listed in the French stupéfiants lists. #

Currently classified as a strictly controlled substance under French national drug scheduling laws (many 2C phenethylamines and named 2‑C derivatives are included in the stupéfiants annexes), with no authorized medical use outside of approved clinical research. The Arrêté and its successive modifications include numerous phenethylamine family compounds and catch‑all structural descriptions used to control many 2C‑type compounds; therefore 2C‑X family members are effectively controlled. #